Amarin Announces Research Evaluating Benefits Of VASCEPA/VAZKEPA To Be Presented At The American College Of Cardiology's Annual Scientific Session & Expo
Amarin Announces Research Evaluating Benefits Of VASCEPA/VAZKEPA To Be Presented At The American College Of Cardiology's Annual Scientific Session & Expo
Amarin宣佈評估VASCEPA/VAZKEPA益處的研究將在美國心臟病學會的年度科學會議和博覽會上發表
-- Subgroup Analyses from REDUCE-IT and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting --
--來自 REDUCE-IT 的子組分析 以及會議上介紹的二十碳五烯乙基（IPE）/二十碳五烯酸（EPA）的機械數據——
DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.
愛爾蘭都柏林和新澤西州布里奇沃特，2024年3月25日（GLOBE NEWSWIRE）——Amarin Corporation plc（納斯達克股票代碼：AMRN）今天宣佈，來自具有里程碑意義的REDUCE-IT結果試驗的更多患者亞組分析以及有關二十碳五烯酸（IPE）/二十碳五烯酸（EPA）的機制數據將在4月的美國心臟病學會年度科學會議和博覽會上公佈 2024 年 6 — 8 日在喬治亞州亞特蘭大舉行。
"The data being featured at ACC.24 continues to support and explain the clinical utility and value of VASCEPA/VAZKEPA (icosapent ethyl), not only in...
醫學博士納比爾·阿巴迪爾說：“ACC.24上公佈...
登入免費觀看全文
登入/註冊